# Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer

> **NCT01763450** · PHASE2 · UNKNOWN · sponsor: **Liaoning Cancer Hospital & Institute** · enrollment: 100 (estimated)

## Conditions studied

- Liver Metastases
- Colorectal Cancer

## Interventions

- **DRUG:** bevacizumab plus chemotherapy

## Key facts

- **NCT ID:** NCT01763450
- **Lead sponsor:** Liaoning Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-09
- **Primary completion:** 2013-05
- **Final completion:** 2014-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2013-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01763450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01763450, "Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01763450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*